Where Travere Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) has been rated by 13 analysts over the past 3 months, with 6 bullish, 4 somewhat bullish, and 3 indifferent ratings. The average 12-month price target is $15.69, a significant decrease from the previous target of $25.70, indicating a potential 38.95% decrease. Analysts' ratings are based on company financials, meetings, and insider communications, and are updated quarterly or after major company updates.
December 15, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Travere Therapeutics has received mixed analyst ratings but the average price target suggests a potential downside, with the new target at $15.69 compared to the previous $25.70.
The significant decrease in the average price target for TVTX by analysts suggests a bearish outlook on the stock's future performance. This could lead to a negative short-term impact on the stock price as the market adjusts to the new analyst expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100